Stealth BioTherapeutics Corp MITO
At closeNov 15, 2022, 4:00 PM EST
- EPS (ttm)
- -0.924
- Shares out
- 73.55M
- P/E ratio
- -0.35
- Forward P/E
- -6.40
- Volume
- 1.30M
- Avg volume
- 201.87K
- Open
- 0.3242
- Previous close
- 0.32
- Day's range
- 0.32 – 0.33
- 52-week range
- 0.1621 – 0.97
- Beta
- 1.46
- Analysts
- Buy
- Price target
- 1.77 (+453.1%)
- Earnings date
- Nov 17, 2022
Key statistics
- Enterprise value
- -14.39M
- PEG ratio
- 0.10
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -26.81M
- Total cash
- 47.13M
- Total debt
- 13.66M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 0.315554
- 200-day average
- 0.368184
Analyst view
Consensus: buy
- Target (low)
- 1.50
- Target (mean)
- 1.77
- Target (high)
- 2.05
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 17, 2022
Expected Nov 17, 2022. Consensus EPS estimate -0.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 17, 2022 | Sep 1, 2022 | -0.01 | — | — | — |
| Oct 6, 2022 | Jun 1, 2022 | -0.02 | — | — | — |
| May 18, 2022 | Mar 1, 2022 | -0.02 | — | — | — |
| Apr 7, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | -0.02 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -0.02 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 23, 2022 | HC Wainwright & Co. | main | — | Buy |
| Jul 1, 2021 | Maxim Group | init | — | Buy |
| Apr 3, 2020 | Nomura | main | — | Buy |
| Apr 2, 2020 | HC Wainwright & Co. | up | Neutral | Buy |
| Dec 23, 2019 | H.C. Wainwright | down | Buy | Neutral |
| Sep 27, 2019 | Cantor Fitzgerald | init | — | Overweight |
About Stealth BioTherapeutics Corp
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Cayman Islands
- Website
- stealthbt.com
News
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday 
77 Biggest Movers From Yesterday 
Stocks That Hit 52-Week Lows On Wednesday 
110 Biggest Movers From Friday - 56 Stocks Moving In Friday's Mid-Day Session
90 Biggest Movers From Yesterday 
Stocks That Hit 52-Week Lows On Friday 
Stocks That Hit 52-Week Lows On Thursday - Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on MITO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.59% | 435,516 | 139.37K | Sep 29, 2022 |
| Brown Brothers Harriman & Co | 0.24% | 174,999 | 56.00K | Sep 29, 2022 |
| Renaissance Technologies, LLC | 0.13% | 96,944 | 31.02K | Sep 29, 2022 |
| Geode Capital Management, LLC | 0.07% | 48,791 | 15.61K | Sep 29, 2022 |
| Boothbay Fund Management, LLC | 0.06% | 43,790 | 14.01K | Sep 29, 2022 |
| Susquehanna International Group, LLP | 0.04% | 30,991 | 9.92K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.07% | 48,791 | 15.61K | Aug 30, 2022 |